Mosaic Mitral Valve: Long-Term Outcomes in Patients Under 65
Trial Parameters
Brief Summary
The safety and efficacy of the Mosaic bioprosthetic heart valves for cardiac valve replacement in the aortic position has been well documented throughout the literature. However, few studies assessing structural valve deficiency, patient outcomes and overall product performance in patients under the age of 65 exists for the Mosaic mitral valve bioprosthetic. This study aims to assess valve efficacy, stability, and post operative outcomes in patients who have received the Mosaic mitral valve prothesis at ProMedica Toledo Hospital and were under the age of 65.
Eligibility Criteria
Inclusion Criteria: * Received the Mosaic Mitral Valve Bioprosthetic at ProMedica Toledo Hospital * Under the age of 65 Exclusion Criteria: * Over the age of 65 * Under the age of 18 * Surgery performed at institutions outside of ProMedica Toledo Hospital